About Delix Therapeutics
Delix Therapeutics is a company based in Menlo Park (United States) founded in 2019 by Nicholas Haft and David E Olson. Delix Therapeutics has raised $70 million across 5 funding rounds from investors including Comerica, HHS and RA Capital. The company has 7 employees as of December 31, 2021. Delix Therapeutics offers products and services including Neuroplastogens. Delix Therapeutics operates in a competitive market with competitors including ATAI, COMPASS Pathways, MindMed, Beckley Psytech and Cybin, among others.
- Headquarter Menlo Park, United States
- Employees 7 as on 31 Dec, 2021
- Founders Nicholas Haft, David E Olson
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Delix Therapeutics, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$70 M (USD)
in 5 rounds
-
Latest Funding Round
$825 K (USD), Grant
Jun 04, 2024
-
Investors
Comerica
& 20 more
-
Employee Count
7
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Delix Therapeutics
Delix Therapeutics offers a comprehensive portfolio of products and services, including Neuroplastogens.
Compounds that induce neuroplasticity to treat brain health conditions.
People of Delix Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Delix Therapeutics
Delix Therapeutics has successfully raised a total of $70M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $825 thousand completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Delix Therapeutics
Delix Therapeutics has secured backing from 21 investors, including institutional and venture fund investors. Prominent investors backing the company include Comerica, HHS and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage startups are invested in by Artis Ventures.
|
Locked | Locked | Locked | |
|
Investment in cannabis industry startups is facilitated by Casa Verde.
|
Locked | Locked | Locked | |
|
Venture capital fund focused on early-stage biotech, life sciences, IT, and multiple sectors
|
Locked | Locked | Locked |
Investor details for Delix Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Delix Therapeutics
Investment portfolio details for Delix Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Delix Therapeutics
Detailed financials for Delix Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Delix Therapeutics Comparisons
Peer comparison for Delix Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Delix Therapeutics
Delix Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ATAI, COMPASS Pathways, MindMed, Beckley Psytech and Cybin, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Therapies for mental disorders, including psilocybin for depression, are developed.
|
|
| Locked | Locked | Locked |
Psychedelic-based therapies for brain health disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of drugs for the treatment of neurological and psychiatric disorders
|
|
| Locked | Locked | Locked |
Psychedelic therapeutics for psychiatric disorders are developed and provided.
|
|
| Locked | Locked | Locked |
Psychedelic-derived therapeutics for mental illnesses are developed.
|
Detailed competitors of Delix Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Delix Therapeutics
Complete news archive for Delix Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Delix Therapeutics
Delix Therapeutics was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Delix Therapeutics is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Delix Therapeutics is a funded company, having raised a total of $70M across 5 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Delix Therapeutics is 7.
Delix Therapeutics was founded in 2019 and is based in Menlo Park, United States. Small molecule-based, non-hallucinogenic versions of psychedelic compounds are developed by the company to address depression, anxiety, and post-traumatic stress disorders. Operations focus on creating therapeutic solutions within the biotechnology sector for multiple neurological conditions, enabling treatment options for healthcare providers.
Delix Therapeutics's top competitors include MindMed, COMPASS Pathways and Beckley Psytech.
Delix Therapeutics offers Neuroplastogens.
Delix Therapeutics has 21 investors. Key investors include Comerica, HHS, RA Capital, Artis Ventures, and Casa Verde.